ClinicalTrials.gg
Status unknownNCT05033847Updated Feb 2, 2023

Clinical Trial on Sequential Immunization of Recombinant COVID-19 Vaccine (CHO Cells) and Inactivated COVID-19 Vaccine (Vero Cells) in Population Aged 18 Years and Above

A Phase 2 interventional study of Recombinant COVID-19 Vaccine (CHO cell) and COVID-19 vaccine (Vero cells) in COVID-19 Pneumonia and Coronavirus Infections, sponsored by National Vaccine and Serum Institute, China. Status unknown at 1 site in United Arab Emirates. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-02-02.

Primary conditionCOVID-19Registry: Coronavirus InfectionsReclassifiedWhy we changed it
Registry
Coronavirus Infections — the first condition term the registry derived for this study.
ClinicalTrials.gg
COVID-19
Why
  1. The study's listed conditions name COVID-19, a narrower term within Coronavirus Infections.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by National Vaccine and Serum Institute, China (part of Sinopharm) · Phase 2, Interventional, and Prevention

The sponsor has not verified this record recently (last verified Jan 2023), so the status shown — last known as Active, not recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
1,800
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 18 studies testing CHO cell in COVID-19 — 1 open to participants now, 1 under way, none of them phase 3. CHO cell · COVID-19.

Enrollment
6th of 18
1,800 · median 714
Started
2021
with 8 others
Phase 2
5 of 18
none open now
Registered
6th of 18
by date
Lead sponsor
2 of 18
National Vaccine and Serum Institute, China

Among the 18 studies testing CHO cell in COVID-19, this one is the 6th largest by enrollment, is one of 9 that started in 2021, is one of 5 in phase 2, and was the 6th registered.

COVID-19

7,994 studies on the registry are indexed under COVID-19; 467 are open to participants now.

Browse COVID-19 studies →

Open to participants now

1 of the 18 studies testing CHO cell in COVID-19 is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About CHO cell

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 356 COVID-19 studies recruiting now, 206 (58%) set no upper age limit and 83 (23%) stop at 75 or younger; 91 take children under 18; 135 take healthy volunteers.

This study: 18 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 18 studies testing CHO cell in COVID-19, or all of them as a file.
02

Study summary

This is randomized, blinded and controlled design. Among the randomly selected subjects who have been vaccinated with two doses of Inactivated COVID-19 vaccine (Vero cell), based on a step-wise approach, the subjects will receive one dose of recombinant COVID-19 vaccine sequentially at different shedules of 1-3 months, 3-6 months and ≥ 6 months after two doses of vaccination, and the subjects vaccinated at different schedules will be randomly assigned to different sequential immunization groups. At the same time, each sequential immunization group will be matched with a control group with the inactivated COVID-19 vaccine (vero cells) as the booster dose.

03

Conditions studied

  • COVID-19 Pneumonia
  • Coronavirus Infections

Browse trials for

Keywords

  • COVID-19
04

In context

COVID-19 Reclassified

7,994 studies on the registry are indexed under COVID-19; 467 are open to participants now.

This study's enrollment of 1,800 is above the median of 102 across 4,366 interventional studies indexed under COVID-19.

Browse COVID-19 studies →

Lead sponsor

National Vaccine and Serum Institute, China is the lead sponsor of 13 studies on the registry; none are open to participants now.

First submitted after National Vaccine and Serum Institute, China became part of Sinopharm.

Compared within COVID-19, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Coronavirus Infections. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age range: populations aged 18 years and above;
  • Judged by the investigator that the health condition is well after inquiry and physical examination;
  • Vaccinated with 2 doses of CNBG inactivated COVID-19 vaccine according to the product insert;
  • Female subjects who are not nursing or pregnant at the time of enrolment (negative urine pregnancy test) and have no family planning within the first 6 months after enrolment. Effective measures have been taken within 2 weeks before inclusion.
  • During the whole follow-up period of the study, be able and willing to complete the whole prescribed study plan; Self has ability to understand the study procedures, the \& voluntarily sign an informed consent form and is able to comply with the requirements of the clinical study protocol.

Exclusion criteria

Exclusion Criteria:

  • Confirmed cases, suspected cases or asymptomatic cases of COVID-19;
  • With a history of SARS and MERS infection (self-report, on-site inquiry);
  • Has vaccinated with any vaccine other than one or more doses of CNBG inactivated COVID-19 vaccine;
  • Axillary temperature ≥ 37.3 ℃ (forehead temperature ≥ 37.8 ℃);
  • Previous severe allergic reactions to vaccination (such as acute allergic reactions, urticaria, dyspnea, angioneurotic edema or abdominal pain) or allergy to known components of recombinant COVID-19 vaccine;
  • Allergic to any component of the study vaccine (e.g. aluminum, histidine, etc.)
  • Known or suspected diseases include:Severe respiratory diseases, severe liver and kidney diseases, hypertension (systolic blood pressure ≥ 150 mmHg, diastolic blood pressure ≥ 90 mmHg), diabetic complications, malignant tumors, various acute diseases or acute attacks of chronic diseases;
  • Has been diagnosed with congenital or acquired immunodeficiency, infection, lymphoma, leukemia or other diseases;
  • Has a history of convulsions, epilepsy, encephalopathy,long term history of alcohol and drug abuse, history of thyroidectomy, infectious diseasesor mental illness or family history(lineal);
  • With Congenital malformation or developmental disorder, genetic defect, severe malnutrition, etc.;
  • Has a history of coagulation dysfunction (e.g. coagulation factors deficiency and coagulation diseases);
  • Absence of spleen or splenectomy, functional absence of spleen caused by any condition
  • Anti -TB (TB) treatment is under way.
  • Patients receiving immunoenhancement or inhibitor therapy within 3 months (continuous oral or IV administration for more than 14 days);
  • Received other vaccines within 14 days before vaccination;
  • Received blood products before within 3 months before vaccination;
  • Received other drugs within 6 months before vaccination;
  • Plan to move before the end of the study or leave the local area for a long time during the scheduled study visit
  • Other circumstances judged by investigators that are not suitable for this clinical trial
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

06

Study design

Phase
Phase 2
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
1,800 participants (actual)

Study arms

  • Experimental
    Subject last vaccination time is within 30-90 days

    Subject have been vaccinated with two doses of Inactivated COVID-19 vaccine (Vero cell).The last vaccination time is within 30-90 days

    Biological: Recombinant COVID-19 Vaccine (CHO cell) · Biological: COVID-19 vaccine (Vero cells)

  • Experimental
    Subject last vaccination time is within 91-180 days

    Subject have been vaccinated with two doses of Inactivated COVID-19 vaccine (Vero cell).The last vaccination time is within 91-180 days

    Biological: Recombinant COVID-19 Vaccine (CHO cell) · Biological: COVID-19 vaccine (Vero cells)

  • Experimental
    Subject last vaccination time more than 181 days

    Subject have been vaccinated with two doses of Inactivated COVID-19 vaccine (Vero cell).The last vaccination time more than 181 days

    Biological: Recombinant COVID-19 Vaccine (CHO cell) · Biological: COVID-19 vaccine (Vero cells)

Interventions

07

What researchers measure

Primary outcomes

  1. GMT of anti- SARS-CoV-2 neutralizing antibody

    Time frame: 14th day after vaccination

  2. GMT of anti- SARS-CoV-2 neutralizing antibody

    Time frame: 28th day after vaccination

  3. 4-fold rise of anti- SARS-CoV-2 neutralizing antibody

    Time frame: 14th day after vaccination

  4. 4-fold rise of anti- SARS-CoV-2 neutralizing antibody

    Time frame: 28th day after vaccination

Secondary outcomes

  1. GMT of anti- SARS-CoV-2 neutralizing antibody

    Time frame: before vaccination

  2. GMT of anti-SARS-CoV-2 IgG antibody

    Time frame: 28th day after vaccination

  3. 4-fold rise of anti- SARS-CoV-2 neutralizing antibody

    Time frame: before vaccination

  4. 4-fold rise of anti- SARS-CoV-2 neutralizing antibody

    Time frame: 28th day after vaccination

  5. GMI of anti-SARS-CoV-2 IgG antibody

    Time frame: before vaccination

  6. GMI of anti-SARS-CoV-2 IgG antibody

    Time frame: 28th day after vaccination

  7. Proportion of neutralizing antibody titer ≥ 1: 16, ≥ 1: 32 and ≥ 1: 64

    Time frame: before vaccination

  8. Proportion of neutralizing antibody titer ≥ 1: 16, ≥ 1: 32 and ≥ 1: 64

    Time frame: 28th day after vaccination

  9. The incidence and serverity of any adverse reactions

    Time frame: within 30 minutes after vaccination

  10. The incidence and serverity of solicited adverse events

    Time frame: within 30 minutes after vaccination

  11. The incidence and severity of adverse reactions

    Time frame: within 0-7 days after vaccination

  12. The incidence and serverity of solicited adverse events

    Time frame: within 0-7 days after vaccination

  13. The incidence and severity of unsolicited adverse reactions

    Time frame: within 8-30 days after vaccination

  14. The incidence and serverity of solicited adverse events

    Time frame: within 8-30 days after vaccination

  15. The incidence of SAE observed

    Time frame: after vaccination and up to 6 months after full course of immunization

  16. The incidence of AESI observed

    Time frame: after vaccination and up to 6 months after full course of immunization

Other outcomes

  1. The vaccine efficay of recombinant COVID-19 vaccine (CHO cells) against COVID-19, severe cases and deaths

    Time frame: 14th day after vaccination

  2. Anti-SARS-CoV-2 neutralizing antibody

    Time frame: 3th month, 6th month, 9th month and 12th month after full course of immunization

  3. Anti-SARS-CoV-2 GMT of IgG antibody

    Time frame: 3th month, 6th month, 9th month and 12th month after full course of immunization

  4. Proportion of neutralizing antibody titer ≥ 1: 16, ≥ 1: 32 and ≥ 1: 64

    Time frame: 3th month, 6th month, 9th month and 12th month after full course of immunization

08

Study locations

1 site
  • Sheikh Khalifa Medical City
    Seha, Abu Dhab 519000, United Arab Emirates
09

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2021 (actual). Primary completion is estimated for Nov 2023, 26 months after the start.

Of 224 industry-sponsored phase 2 interventional studies under COVID-19, half reached primary completion within 8 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 13. This study's planned 26 months is above that.

Counting every sponsor, half of 583 studies reached it within 9 months; a quarter within 5 and three quarters within 16.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 30, 2021
First posted
Sep 5, 2021
StartActual
Sep 12, 2021
Primary completionEst.
Nov 2023
CompletionEst.
Jan 2024
Last update
Feb 2, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 2, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05033847
Responsible party
Sponsor
First posted
Sep 5, 2021
Start date
Sep 12, 2021
Primary completion
Nov 2023 (estimated)
Completion
Jan 2024 (estimated)
Last update
Feb 2, 2023

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Jan 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: CHO cell · Vero cell line

Start the discussion